Coverage of PreveCeutical Medical (PRVCF, PREV) has been updated with a discussion of recent accomplishments. PreveCeutical is an early stage life sciences company with a focus on compounds using natural substances for health and wellness products. The Company has licensed a clutch of natural health products for sleep, pain and anxiety treatment, including a commercially-proven blue scorpion venom solution. PreveCeutical intends to bring these unregulated products to market to generate revenue in the near-term that could be used to financial corporate activities as well as research and development work on additional compounds.
The most advanced project in the development program is the Sol-Gel drug delivery system originated at UniQuest. The Sol-Gel nose-to-brain approach is potentially helpful in reducing side effects and increasing drug effectiveness. Cannabinoids are the first compounds under testing.
Additional projects in the pipeline are similarly aimed at using naturally derived compounds to treat diseases with large patient populations.
· Smart RNA Dual Gene Therapy for the treatment of obesity and early stage diabetes
· Peptide and protein identification in the venom of Caribbean blue scorpion venom for the purposes of engineering ‘nature identical’ compounds
· Peptide library using the University of Queensland proprietary ‘disulfide linker’ technology licensed by PreveCeutical Medical.
The full 10-page report can be viewed by clicking on the image below.
Please note disclosures and disclaimers at the end of all Crystal Equity Research publications.